A5012326482- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- vaccines and immunoinformatics approaches
- Chronic Myeloid Leukemia Treatments
- Platelet Disorders and Treatments
- Chromosomal and Genetic Variations
- Hematopoietic Stem Cell Transplantation
- Genetics, Bioinformatics, and Biomedical Research
- Biological Research and Disease Studies
- Cancer Mechanisms and Therapy
- Insect Resistance and Genetics
- Virology and Viral Diseases
- Cancer therapeutics and mechanisms
- Renal Transplantation Outcomes and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Viral Infectious Diseases and Gene Expression in Insects
Mayo Clinic in Arizona
2020-2025
Mayo Clinic Hospital
2022-2025
Mayo Clinic in Florida
2022-2024
WinnMed
2024
Adaptive Biotechnologies (United States)
2022
Translational Genomics Research Institute
2022
City Of Hope National Medical Center
2022
City of Hope
2022
Princess Margaret Cancer Centre
2022
University Health Network
2022
Abstract Investigating venetoclax (VTX) resistance in multiple myeloma (MM) is crucial for the development of novel therapeutic strategies to tackle resistance. We conducted a multi-omic characterization established VTX-resistant isogenic human cell lines (HMCL) and primary MM patient samples pre- post-VTX treatment. Transcriptomic proteomic analysis revealed that was largely associated with BCL-2 family protein dysregulation, including upregulation anti-apoptotic proteins such as MCL-1,...
Abstract Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is associated improved survival outcomes. The role of highly sensitive next generation sequencing (NGS) MRD combination functional imaging remains to be validated. We performed a retrospective analysis on MM who underwent frontline autologous stem cell transplant (ASCT). Patients were evaluated at day 100 post-ASCT NGS-MRD positron emission tomography (PET-CT). ≥ 2...
Abstract Introduction: Multiple myeloma (MM) is a B-cell-derived malignancy associated with immune dysregulation. Anti-CD38 monoclonal antibodies (mAbs) therapies have shown improved outcomes in patients MM. Silbermann et al. showed that anti-CD38 mAb-containing lead to profound hypogammaglobulinemia and reduction Ig gene repertoire. The effect of modern such as CAR-T bispecific (BsAbs) on B-cell repertoire has not been well described. In this study, we sought investigate the these Methods:...
Fluorescence in situ hybridization (FISH) for plasma cell neoplasms (PCNs) requires (PC) identification or purification strategies to optimize results. We compared the efficacy of cytoplasmic immunoglobulin FISH (cIg-FISH) and fluorescence-activated sorting (FACS-FISH) a clinical laboratory setting.
Abstract Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is associated improved survival outcomes. The role of highly sensitive next generation sequencing (NGS) MRD combination functional imaging remains to be validated. We performed a retrospective analysis on MM who underwent frontline autologous stem cell transplant (ASCT). Patients were evaluated at day 100 post-ASCT NGS positron emission tomography (PET-CT). ≥ 2...